2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France

被引：31

作者：

Franchet, Camille ^{[1
]}

Djerroudi, Lounes ^{[1
]}

Maran-Gonzalez, Aurelie ^{[1
]}

Abramovici, Olivia ^{[1
]}

Antoine, Martine ^{[1
]}

Becette, Veronique ^{[1
]}

Berghian, Anca ^{[1
]}

Blanc-Fournier, Cecile ^{[1
]}

Brabencova, Eva ^{[1
]}

Charafe-Jauffret, Emmanuelle ^{[1
]}

Chenard, Marie-Pierre ^{[1
]}

Dauplat, Marie-Melanie ^{[1
]}

Delree, Paul ^{[1
]}

Duprez-Paumier, Raphaelle ^{[1
]}

Fleury, Clemence ^{[1
]}

Ghnassia, Jean-Pierre ^{[1
]}

Haudebourg, Juliette ^{[1
]}

Leroux, Agnes ^{[1
]}

MacGrogan, Gaetan ^{[1
]}

Mathieu, Marie-Christine ^{[1
]}

Michenet, Patrick ^{[1
]}

Penault-Llorca, Frederique ^{[1
]}

Poulet, Bruno ^{[1
]}

Robin, Yves Marie ^{[1
]}

Roger, Pascal ^{[1
]}

Russ, Elisabeth ^{[1
]}

Tixier, Lucie ^{[1
]}

Treilleux, Isabelle ^{[1
]}

Valent, Alexander ^{[1
]}

Verriele, Veronique ^{[1
]}

Vincent-Salomon, Anne ^{[1
]}

Arnould, Laurent ^{[1
]}

Lacroix-Triki, Magali ^{[1
]}

机构：

[1] Grp Etud Facteurs Pronost Immunohistochim Canc Se, Unicanc, 101 Rue Tolbiac, F-75654 Paris 13, France

来源：

ANNALES DE PATHOLOGIE | 2021年 / 41卷 / 06期

关键词：

Breast cancer; Guidelines; HER2; Immunohistochemistry; In situ hybridization; ERBB2; PATHOLOGICAL COMPLETE RESPONSE; IN-SITU HYBRIDIZATION; FACTOR RECEPTOR 2; GENE AMPLIFICATION; ADJUVANT TRASTUZUMAB; ESTROGEN-RECEPTOR; OPEN-LABEL; MULTICENTER; EXPRESSION; MUTATIONS;

D O I：

10.1016/j.annpat.2021.07.014

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The last international guidelines on HER2 determination in breast cancer have been updated in 2018 by the American Society of Clinical Oncology and College of American Pathologists, on the basis of a twenty-year practice and results of numerous clinical trials. Moreover, the emerging HER2-low concept for 1+ and 2+ non amplified breast cancers lead to refine French practices for HER2 status assessment. The GEFPICS group, composed of expert pathologists, herein presents the latest French recommendations for HER2 status evaluation in breast cancer, taking into account the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, HER2 status assessment remains one of the most important biomarkers in breast cancer and its quality guaranties the optimal patients' care. French pathologists' commitment in theranostic biomarker quality is more than ever required to provide the most efficient cares in oncology. (C) 2021 Elsevier Masson SAS. All rights reserved.

引用

页码：507 / 520

页数：14

共 50 条

[31] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Kurozumi, Sasagu
Padilla, Mary
Kurosumi, Masafumi
Matsumoto, Hiroshi
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Ranger-Moore, Jim
Allred, D. Craig
Dennis, Eslie
Nitta, Hiroaki
BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
[32] HER2/neu in the management of invasive breast cancer
Meric, F
Hung, MC
Hortobagyi, GN
Hunt, KK
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2002, 194 (04) : 488 - 501
[33] Molecular Assessment of HER2 in Breast Cancer
Maddox, Adam L.
Brehove, Matthew S.
Tobin, Steven J.
Wakefield, Devin L.
Eliato, Kiarash R.
Alva-Ornelas, Jackelyn
Jones, Veronica
Schmolze, Daniel
Mortimer, Joanne
Seewaldt, Victoria L.
Jovanovic-Talisman, Tijana
BIOPHYSICAL JOURNAL, 2021, 120 (03) : 359A - 359A
[34] Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists
Bornstein-Quevedo, Leticia
de Anda-Gonzalez, Jazmin
Lara-Torres, Cesar Octavio
Flores-Gutierrez, Juan Pablo
Dorantes-Heredia, Rita
Bautista-Pina, Veronica
Zaragoza-Vargas, Perla
Alcaraz-Wong, Aldo
Soto-Sanudo, Ana Karen
Mendoza-Ramirez, Saulo
Salamanca-Garcia, Moises
Loyola-Rodriguez, Georgina
Gomez-Macias, Gabriela Sofia
Murguia-Perez, Mario
De Luna-Sanchez, Marcela
Villalobos-Valencia, Ricardo
Talamantes, Enrique
Arce-Salinas, Claudia
JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (05):
[35] Histologic analysis according to HER2 gene status in HER2 2 + invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations
Hye Won Hwang
Soon Auck Hong
Seok Jin Nam
Seok Won Kim
Jeong Eon Lee
Jong-Han Yu
Se Kyung Lee
Soo Youn Cho
Eun Yoon Cho
Virchows Archiv, 2022, 480 : 749 - 758
[36] BREAST CANCER Updated guideline recommendations for HER2 testing
Rakha, Emad A.
Ellis, Ian O.
NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (01) : 8 - 9
[37] HER2 status in elderly women with breast cancer
Laird-Fick, Heather S.
Gardiner, Joseph C.
Tokala, Hemasri
Patel, Priyank
Wei, Sainan
Dimitrov, Nikolay V.
JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (04) : 362 - 367
[38] Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status
Penault-Llorca, Frederique
Coudry, Renata A.
Hanna, Wedad M.
Osamura, Robert Y.
Rueschoff, Josef
Viale, Giuseppe
BREAST, 2013, 22 (02): : 200 - 202
[39] Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number
Jang, Min Hye
Kim, Eun Joo
Kim, Hyun Jeong
Chung, Yul Ri
Park, So Yeon
BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (01) : 67 - 77
[40] Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number
Min Hye Jang
Eun Joo Kim
Hyun Jeong Kim
Yul Ri Chung
So Yeon Park
Breast Cancer Research and Treatment, 2015, 153 : 67 - 77

← 1 2 3 4 5 →